Can Luspatercept treat myeloid dysplasia?

Luspatercept (Luspatercept) can be used to treat a disease of abnormal proliferation of bone marrow called myelodysplastic syndrome (MDS). Myelodysplastic syndromes are a group of rare but serious blood disorders that typically manifest as an abnormal proliferation of hematopoietic cells in the bone marrow, leading to anemia, bleeding tendencies, and susceptibility to infection.

The mechanism of action of Rotercept is closely related to the pathophysiological process of MDS. It improves the process of red blood cell production and maturation by mimicking a protein in the body called activating TGF-beta superfamily receptors. This process helps increase the quantity and quality of red blood cells, thereby increasing the patient's hemoglobin levels and improving anemia symptoms.

Clinical studies and trials have confirmed the efficacy of Rotacept in some patients with myelodysplastic syndrome. Patients may see improvements over time with treatment, including increases in hemoglobin levels and relief from anemia symptoms. However, the time to onset of response varies depending on individual patient differences, disease severity, and treatment regimen.

Treating myelodysplastic syndrome usually requires thorough evaluation and supervision by a doctor to determine the most appropriate treatment plan. Patients should always use Rotacept according to their doctor's recommendations and undergo regular follow-up and monitoring during treatment to ensure optimal treatment effectiveness and safety. If you or someone you know has myelodysplastic syndrome, it is recommended to consult a medical professional for detailed diagnosis and treatment advice.

Rotexip is already on the market in China and has been included in medical insurance. Patients can purchase it domestically. Please consult the local hospital pharmacy for specific prices. There are only original drugs for Rotesip abroad, mainly European ones, with a price of more than 10,000 yuan.